← back to search
Ruben Sanchez de la Rosa
Novartis (Switzerland) · CH
Area of research
Molecular Biology · Neurology
Research interest
Research interests include Tolerability, Ofatumumab, Medicine, Internal medicine, and Adverse effect.
h-index
—
citations
0
works
1
NIH funding
—
primary concept
—
email
✉ Find email ↗
Recent publications
Effectiveness and Tolerability of Ofatumumab Versus First-line DMTs in Early RMS Patients: Phase 3b STHENOS Study Design
HAL (Le Centre pour la Communication Scientifique Directe)
2021
cited by
0
position: middle
Grants
No grants ingested yet.
Frequent collaborators
Diego Centonze
· Agostino Gemelli University Polyclinic
1
papers (2021–2021)
—
·
1
papers (2021–2021)
Xavier Montalbán
· Fundació ACE
1
papers (2021–2021)
—
·
1
papers (2021–2021)
Éric Thouvenot
· Université de Nîmes
1
papers (2021–2021)
Leilani T Nillos
· Novartis (Switzerland)
1
papers (2021–2021)
Ralf A. Linker
· Klinik und Poliklinik für Neurologie
1
papers (2021–2021)
Benjamin Turner
· London School of Hygiene & Tropical Medicine
1
papers (2021–2021)